Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection

Abstract Background Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid imm...

Full description

Saved in:
Bibliographic Details
Published inOpen forum infectious diseases Vol. 9; no. 12; p. ofac625
Main Authors Ekström, Nina, Haveri, Anu, Solastie, Anna, Virta, Camilla, Österlund, Pamela, Nohynek, Hanna, Nieminen, Tuomo, Ivaska, Lauri, Tähtinen, Paula A, Lempainen, Johanna, Jalkanen, Pinja, Julkunen, Ilkka, Palmu, Arto A, Melin, Merit
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.12.2022
Subjects
Online AccessGet full text
ISSN2328-8957
2328-8957
DOI10.1093/ofid/ofac625

Cover

Loading…
Abstract Abstract Background Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects. Methods We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination. Results A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses. Conclusions Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron.
AbstractList Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects.BackgroundPrevious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects.We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination.MethodsWe measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination.A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses.ResultsA single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses.Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron.ConclusionsHybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron.
Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects. We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination. A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses. Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron.
Background Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects. Methods We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination. Results A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses. Conclusions Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron.
Abstract Background Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects. Methods We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination. Results A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses. Conclusions Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron.
Author Haveri, Anu
Österlund, Pamela
Lempainen, Johanna
Melin, Merit
Nieminen, Tuomo
Palmu, Arto A
Julkunen, Ilkka
Ivaska, Lauri
Tähtinen, Paula A
Virta, Camilla
Nohynek, Hanna
Jalkanen, Pinja
Ekström, Nina
Solastie, Anna
Author_xml – sequence: 1
  givenname: Nina
  surname: Ekström
  fullname: Ekström, Nina
  email: nina.ekstrom@thl.fi
– sequence: 2
  givenname: Anu
  surname: Haveri
  fullname: Haveri, Anu
– sequence: 3
  givenname: Anna
  surname: Solastie
  fullname: Solastie, Anna
– sequence: 4
  givenname: Camilla
  surname: Virta
  fullname: Virta, Camilla
– sequence: 5
  givenname: Pamela
  surname: Österlund
  fullname: Österlund, Pamela
– sequence: 6
  givenname: Hanna
  surname: Nohynek
  fullname: Nohynek, Hanna
– sequence: 7
  givenname: Tuomo
  surname: Nieminen
  fullname: Nieminen, Tuomo
– sequence: 8
  givenname: Lauri
  surname: Ivaska
  fullname: Ivaska, Lauri
– sequence: 9
  givenname: Paula A
  surname: Tähtinen
  fullname: Tähtinen, Paula A
– sequence: 10
  givenname: Johanna
  surname: Lempainen
  fullname: Lempainen, Johanna
– sequence: 11
  givenname: Pinja
  surname: Jalkanen
  fullname: Jalkanen, Pinja
– sequence: 12
  givenname: Ilkka
  surname: Julkunen
  fullname: Julkunen, Ilkka
– sequence: 13
  givenname: Arto A
  surname: Palmu
  fullname: Palmu, Arto A
– sequence: 14
  givenname: Merit
  surname: Melin
  fullname: Melin, Merit
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36519113$$D View this record in MEDLINE/PubMed
BookMark eNp9ks9vFCEUx4mpsT9vng2JBz10LAwwDJcmm9Vqk0ZNR-uRMAzTspmFFZg29W_oHy2T3Zq1iV54vLzP--Z94e2DHeedAeAlRu8wEuTE97bLh9JVyZ6BvZKUdVELxne27rvgKMYFQghjxBAXL8AuqRgWGJM98NCk4N01_GzGFNRgf9mczFyyre_u4aWJK--iiTB52Mwum2Lur4oSXqlglUsRnvlh8HdTj4JNDoPJNa2tM_C9jwZaB5uxXRid2R823cCvwdxaP8ZttXPXZ8B6dwie92qI5mgTD8D3sw_f5p-Kiy8fz-ezi0JTSlNBSbZOCK0F7mjNlepbxBFGigpuOKKqLylhvO-QQGVVc20q3CHNuSZUqFaQA3C61l2N7dJ02rjJu1wFu1ThXnpl5d8VZ2_ktb-VglPGa5QF3m4Egv85mpjk0kZthkE5k83JkjNasxoLmtHXT9CFH4PL9iTBHGNeMT4Jvtqe6M8ojx-VgXIN6OBjDKaX2iY1PVoe0A4SIzkthJwWQm4WIjcdP2l61P0H_maN-3H1f_I3PGLGBQ
CitedBy_id crossref_primary_10_22207_JPAM_18_3_48
crossref_primary_10_3390_diagnostics14070720
crossref_primary_10_3390_biom13101452
crossref_primary_10_3389_fimmu_2023_1152695
crossref_primary_10_1007_s10517_023_05951_7
Cites_doi 10.1038/s41586-022-04778-y
10.1016/j.ebiom.2021.103656
10.1002/eji.202149535
10.1126/science.abh1282
10.1001/jama.2021.11656
10.3389/fimmu.2022.916686
10.1186/s12967-021-03208-3
10.1038/s41586-021-03696-9
10.1038/s41467-021-24285-4
10.1016/j.xcrm.2021.100486
10.2807/1560-7917.ES.2020.25.11.2000266
10.1038/s41591-022-01715-4
10.1001/jama.2021.15125
10.1016/j.ijid.2021.08.052
10.1056/NEJMc2101667
10.1038/s43856-022-00130-7
10.1128/Spectrum.01131-21
10.1128/mBio.00902-21
10.1038/s41591-021-01325-6
10.1056/NEJMoa2119497
10.1056/NEJMoa2027906
10.1016/S2666-5247(21)00275-5
10.1016/j.chom.2021.01.014
10.1001/jama.2021.3341
10.1016/S1473-3099(22)00140-2
10.3390/v14040802
10.1126/science.abg9175
10.1021/acs.jcim.1c01451
10.1126/sciimmunol.abn8014
10.1002/eji.202149785
10.1016/j.cell.2022.01.011
10.1016/S1473-3099(22)00143-8
10.1016/S0140-6736(21)00527-4
10.1016/S0140-6736(21)00501-8
10.1016/j.isci.2022.103743
10.1016/S0140-6736(21)00502-X
10.1126/sciimmunol.abi6950
10.1371/journal.pone.0263942
10.1038/s41467-022-28544-w
10.1001/jama.2021.22898
10.1128/mBio.02656-21
ContentType Journal Article
Copyright The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022
The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022
– notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
– notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID TOX
AAYXX
CITATION
NPM
3V.
7X7
7XB
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1093/ofid/ofac625
DatabaseName Oxford Journals Open Access Collection
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Public Health
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Publicly Available Content Database

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: TOX
  name: Oxford Journals Open Access Collection
  url: https://academic.oup.com/journals/
  sourceTypes: Publisher
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2328-8957
ExternalDocumentID PMC9745780
36519113
10_1093_ofid_ofac625
10.1093/ofid/ofac625
Genre Journal Article
GrantInformation_xml – fundername: ;
– fundername: ;
  grantid: 336410, 336431
– fundername: ;
  grantid: 5360-cc2fc
GroupedDBID 0R~
53G
5VS
7X7
8C1
8FI
8FJ
AAFWJ
AAMVS
AAPXW
AAVAP
ABDBF
ABEJV
ABGNP
ABPTD
ABUWG
ABXVV
ACGFS
ACUHS
ADBBV
ADHZD
ADPDF
ADRAZ
AENZO
AFKRA
AFPKN
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AMNDL
AOIJS
BAWUL
BAYMD
BCNDV
BENPR
CCPQU
CIDKT
DIK
EBS
EJD
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
IAO
IHR
ITC
KQ8
KSI
M48
M~E
O9-
OAWHX
OJQWA
OK1
OVD
OVEED
PEELM
PIMPY
ROL
RPM
TEORI
TJX
TOX
UKHRP
AAYXX
CITATION
PHGZM
PHGZT
AAPPN
AFULF
BTTYL
NPM
ROX
3V.
7XB
8FK
AZQEC
COVID
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c444t-43093334891d487aafb07010a497e704af24357fd0902687ce61d0c77c349ab93
IEDL.DBID BENPR
ISSN 2328-8957
IngestDate Thu Aug 21 18:39:32 EDT 2025
Fri Jul 11 09:09:41 EDT 2025
Fri Jul 25 21:39:49 EDT 2025
Wed Feb 19 02:26:14 EST 2025
Tue Jul 01 00:49:16 EDT 2025
Thu Apr 24 22:52:41 EDT 2025
Wed Apr 02 07:03:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords previous infection
neutralizing antibodies
SARS-CoV-2
variants of concern
hybrid immunity
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
https://creativecommons.org/licenses/by/4.0
The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c444t-43093334891d487aafb07010a497e704af24357fd0902687ce61d0c77c349ab93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Potential conflicts of interest. The Finnish Institute for Health and Welfare conducts a Public-Private Partnership with vaccine manufacturers and has received research funding for studies unrelated to COVID-19 from GlaxoSmithKline Vaccines (N.E., C.V., A.A.P., and M.M. as investigators), Pfizer (A.A.P.), and Sanofi Pasteur (A.A.P., T.N.). The other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
OpenAccessLink https://www.proquest.com/docview/3171176570?pq-origsite=%requestingapplication%
PMID 36519113
PQID 3171176570
PQPubID 7089189
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9745780
proquest_miscellaneous_2754858194
proquest_journals_3171176570
pubmed_primary_36519113
crossref_citationtrail_10_1093_ofid_ofac625
crossref_primary_10_1093_ofid_ofac625
oup_primary_10_1093_ofid_ofac625
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-12-01
PublicationDateYYYYMMDD 2022-12-01
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-01
  day: 01
PublicationDecade 2020
PublicationPlace US
PublicationPlace_xml – name: US
– name: United States
– name: Oxford
PublicationTitle Open forum infectious diseases
PublicationTitleAlternate Open Forum Infect Dis
PublicationYear 2022
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Liu (2022121311132761200_ofac625-B5) 2021; 29
Rusanen (2022121311132761200_ofac625-B26) 2021; 12
Haveri (2022121311132761200_ofac625-B3) 2022; 52
Cerqueira-Silva (2022121311132761200_ofac625-B20) 2022; 22
Walls (2022121311132761200_ofac625-B34) 2022; 185
Vicenti (2022121311132761200_ofac625-B17) 2021; 112
Saadat (2022121311132761200_ofac625-B28) 2021; 325
Bates (2022121311132761200_ofac625-B33) 2022; 327
Bobrovitz (2022121311132761200_ofac625-B40)
Walsh (2022121311132761200_ofac625-B43) 2020; 383
Bates (2022121311132761200_ofac625-B44) 2021; 326
Hammerman (2022121311132761200_ofac625-B18) 2022; 386
Singh (2022121311132761200_ofac625-B42)
Siracusano (2022121311132761200_ofac625-B11) 2022; 20
Stamatatos (2022121311132761200_ofac625-B35) 2021; 372
van Gils MJ (2022121311132761200_ofac625-B32) 2021; 3
Chen (2022121311132761200_ofac625-B6) 2022; 62
Marcotte (2022121311132761200_ofac625-B2) 2022; 25
Nordström (2022121311132761200_ofac625-B19) 2022; 22
Angyal (2022121311132761200_ofac625-B10) 2022; 3
Bates (2022121311132761200_ofac625-B14) 2022; 7
Wratil (2022121311132761200_ofac625-B37) 2022; 28
Goel (2022121311132761200_ofac625-B15) 2021; 6
Ontañón (2022121311132761200_ofac625-B8) 2021; 73
Zou (2022121311132761200_ofac625-B4) 2022; 13
Prendecki (2022121311132761200_ofac625-B29) 2021; 397
Miyamoto (2022121311132761200_ofac625-B38) 2022; 3
Reynolds (2022121311132761200_ofac625-B30) 2021; 372
Steensels (2022121311132761200_ofac625-B9) 2021; 326
Wang (2022121311132761200_ofac625-B31) 2021; 595
Muecksch (2022121311132761200_ofac625-B36) 2022; 607
Haveri (2022121311132761200_ofac625-B25) 2020; 25
Kristiansen (2022121311132761200_ofac625-B24) 2021; 397
Ebinger (2022121311132761200_ofac625-B7) 2021; 27
Jalkanen (2022121311132761200_ofac625-B21) 2021; 12
Nguyen P (2022121311132761200_ofac625-B22) 2022; 2
Haveri (2022121311132761200_ofac625-B1) 2021; 51
Lee (2022121311132761200_ofac625-B41) 2022; 13
Ibarrondo (2022121311132761200_ofac625-B13) 2021; 12
Stouten (2022121311132761200_ofac625-B39) 2022; 14
Romero-Ibarguengoitia (2022121311132761200_ofac625-B12) 2022; 17
Solastie (2022121311132761200_ofac625-B23) 2021; 9
Manisty (2022121311132761200_ofac625-B27) 2021; 397
Krammer (2022121311132761200_ofac625-B16) 2021; 384
References_xml – volume: 607
  start-page: 128
  year: 2022
  ident: 2022121311132761200_ofac625-B36
  article-title: Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
  publication-title: Nature
  doi: 10.1038/s41586-022-04778-y
– volume: 73
  start-page: 103656
  year: 2021
  ident: 2022121311132761200_ofac625-B8
  article-title: Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: kinetics and durability of the humoral immune response
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2021.103656
– volume: 51
  start-page: 3202
  year: 2021
  ident: 2022121311132761200_ofac625-B1
  article-title: Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans
  publication-title: Eur J Immunol
  doi: 10.1002/eji.202149535
– volume: 372
  start-page: 1418
  year: 2021
  ident: 2022121311132761200_ofac625-B30
  article-title: Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
  publication-title: Science
  doi: 10.1126/science.abh1282
– volume: 326
  start-page: 868
  year: 2021
  ident: 2022121311132761200_ofac625-B44
  article-title: Age-dependent neutralization of SARS-CoV-2 and P.1 variant by vaccine immune serum samples
  publication-title: JAMA
  doi: 10.1001/jama.2021.11656
– volume: 13
  start-page: 916686
  year: 2022
  ident: 2022121311132761200_ofac625-B41
  article-title: Prior vaccination exceeds prior infection in eliciting innate and humoral immune responses in Omicron infected outpatients
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.916686
– volume: 20
  start-page: 22
  year: 2022
  ident: 2022121311132761200_ofac625-B11
  article-title: Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2
  publication-title: J Transl Med
  doi: 10.1186/s12967-021-03208-3
– volume: 595
  start-page: 426
  year: 2021
  ident: 2022121311132761200_ofac625-B31
  article-title: Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year
  publication-title: Nature
  doi: 10.1038/s41586-021-03696-9
– volume: 12
  start-page: 3991
  year: 2021
  ident: 2022121311132761200_ofac625-B21
  article-title: COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-24285-4
– volume: 3
  start-page: 100486
  year: 2021
  ident: 2022121311132761200_ofac625-B32
  article-title: A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
  publication-title: Cell Rep Med
  doi: 10.1016/j.xcrm.2021.100486
– volume: 25
  start-page: 2000266
  year: 2020
  ident: 2022121311132761200_ofac625-B25
  article-title: Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2020.25.11.2000266
– volume: 3
  start-page: 249
  year: 2022
  ident: 2022121311132761200_ofac625-B38
  article-title: Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
  publication-title: Med (N Y)
– volume: 28
  start-page: 496
  year: 2022
  ident: 2022121311132761200_ofac625-B37
  article-title: Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern
  publication-title: Nat Med
  doi: 10.1038/s41591-022-01715-4
– volume: 326
  start-page: 1533
  year: 2021
  ident: 2022121311132761200_ofac625-B9
  article-title: Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273
  publication-title: JAMA
  doi: 10.1001/jama.2021.15125
– volume: 112
  start-page: 40
  year: 2021
  ident: 2022121311132761200_ofac625-B17
  article-title: Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2021.08.052
– ident: 2022121311132761200_ofac625-B40
  article-title: Protective effectiveness of prior SARS-CoV-2 infection and hybrid immunity against Omicron infection and severe disease: a systematic review and meta-regression
  publication-title: MedRxiv
– volume: 384
  start-page: 1372
  year: 2021
  ident: 2022121311132761200_ofac625-B16
  article-title: Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2101667
– volume: 2
  start-page: 65
  year: 2022
  ident: 2022121311132761200_ofac625-B22
  article-title: The phylodynamics of SARS-CoV-2 during 2020 in Finland
  publication-title: Commun Med (Lond)
  doi: 10.1038/s43856-022-00130-7
– volume: 9
  start-page: e0113121
  year: 2021
  ident: 2022121311132761200_ofac625-B23
  article-title: A highly sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA, and IgM class antibodies
  publication-title: Microbiol Spectr
  doi: 10.1128/Spectrum.01131-21
– volume: 12
  start-page: e00902
  year: 2021
  ident: 2022121311132761200_ofac625-B26
  article-title: A generic, scalable, and rapid time-resolved Förster resonance energy transfer-based assay for antigen detection-SARS-CoV-2 as a proof of concept
  publication-title: mBio
  doi: 10.1128/mBio.00902-21
– volume: 27
  start-page: 981
  year: 2021
  ident: 2022121311132761200_ofac625-B7
  article-title: Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01325-6
– volume: 386
  start-page: 1221
  year: 2022
  ident: 2022121311132761200_ofac625-B18
  article-title: Effectiveness of the BNT162b2 vaccine after recovery from COVID-19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2119497
– volume: 383
  start-page: 2439
  year: 2020
  ident: 2022121311132761200_ofac625-B43
  article-title: Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2027906
– volume: 3
  start-page: e21
  year: 2022
  ident: 2022121311132761200_ofac625-B10
  article-title: T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
  publication-title: Lancet Microbe
  doi: 10.1016/S2666-5247(21)00275-5
– volume: 29
  start-page: 477
  year: 2021
  ident: 2022121311132761200_ofac625-B5
  article-title: Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.01.014
– volume: 325
  start-page: 1467
  year: 2021
  ident: 2022121311132761200_ofac625-B28
  article-title: Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2
  publication-title: JAMA
  doi: 10.1001/jama.2021.3341
– volume: 22
  start-page: 791
  year: 2022
  ident: 2022121311132761200_ofac625-B20
  article-title: Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(22)00140-2
– volume: 14
  start-page: 802
  year: 2022
  ident: 2022121311132761200_ofac625-B39
  article-title: Incidence and risk factors of COVID-19 vaccine breakthrough infections: a prospective cohort study in Belgium
  publication-title: Viruses
  doi: 10.3390/v14040802
– volume: 372
  start-page: 1413
  year: 2021
  ident: 2022121311132761200_ofac625-B35
  article-title: MRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
  publication-title: Science
  doi: 10.1126/science.abg9175
– volume: 62
  start-page: 412
  year: 2022
  ident: 2022121311132761200_ofac625-B6
  article-title: Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance
  publication-title: J Chem Inf Model
  doi: 10.1021/acs.jcim.1c01451
– volume: 7
  start-page: eabn8014
  year: 2022
  ident: 2022121311132761200_ofac625-B14
  article-title: Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.abn8014
– volume: 52
  start-page: 816
  year: 2022
  ident: 2022121311132761200_ofac625-B3
  article-title: Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
  publication-title: Eur J Immunol
  doi: 10.1002/eji.202149785
– volume: 185
  start-page: 872
  year: 2022
  ident: 2022121311132761200_ofac625-B34
  article-title: SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
  publication-title: Cell
  doi: 10.1016/j.cell.2022.01.011
– volume: 22
  start-page: 781
  year: 2022
  ident: 2022121311132761200_ofac625-B19
  article-title: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(22)00143-8
– volume: 397
  start-page: 1347
  year: 2021
  ident: 2022121311132761200_ofac625-B24
  article-title: WHO international standard for anti-SARS-CoV-2 immunoglobulin
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00527-4
– volume: 397
  start-page: 1057
  year: 2021
  ident: 2022121311132761200_ofac625-B27
  article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00501-8
– volume: 25
  start-page: 103743
  year: 2022
  ident: 2022121311132761200_ofac625-B2
  article-title: Immunity to SARS-CoV-2 up to 15 months after infection
  publication-title: iScience
  doi: 10.1016/j.isci.2022.103743
– volume: 397
  start-page: 1178
  year: 2021
  ident: 2022121311132761200_ofac625-B29
  article-title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00502-X
– volume: 6
  start-page: eabi6950
  year: 2021
  ident: 2022121311132761200_ofac625-B15
  article-title: Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.abi6950
– ident: 2022121311132761200_ofac625-B42
  article-title: Ba.1 and BA.2 sub-lineages of Omicron variant have comparable replication kinetics and susceptibility to neutralization by antibodies
  publication-title: MedRxiv
– volume: 17
  start-page: e0263942
  year: 2022
  ident: 2022121311132761200_ofac625-B12
  article-title: Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0263942
– volume: 13
  start-page: 852
  year: 2022
  ident: 2022121311132761200_ofac625-B4
  article-title: Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-28544-w
– volume: 327
  start-page: 179
  year: 2022
  ident: 2022121311132761200_ofac625-B33
  article-title: Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection
  publication-title: JAMA
  doi: 10.1001/jama.2021.22898
– volume: 12
  start-page: e0265621
  year: 2021
  ident: 2022121311132761200_ofac625-B13
  article-title: Previous infection combined with vaccination produces neutralizing antibodies with potency against SARS-CoV-2 variants
  publication-title: mBio
  doi: 10.1128/mBio.02656-21
SSID ssj0001105079
Score 2.2742026
Snippet Abstract Background Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have...
Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection...
Background Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from...
SourceID pubmedcentral
proquest
pubmed
crossref
oup
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage ofac625
SubjectTerms Infections
Major
Severe acute respiratory syndrome coronavirus 2
Vaccines
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB6VIiEuiPJMaZGR4IQMceLEmwOqVoVVQWoPXbb0FtmO3a60SqCbqpTfwI_uTOJd7VY8LokUj5PIM7a_GX8eA7xOlHeJFY6rPPZcZk5y7YqKe-HwKXaoqmdbHOUHE_nlNDvdgMVpo6EB53907eg8qcnF7N3PH9d72OE_hGRI71ELFV60RSx_B-7inJSTfR8GoN9FWxBGxKoIzPfbldbmpLV9bitw8zZrcmUaGj2EBwE_smGv8C3YcPUjuHcYVsgfw-8xxbbP2JG77GIYv3BqYsO6nZqmumbHPSPWzVnbsPHweMz3mxOesBP0mIkQw0ZoFs0V1dFsjLeZwzJLr2Yfm7lj05rhUEOxmzn7Nm3PGaWAIhrt6ts-B4JX_QQmo09f9w94OHGBWyllyyWti9Le3EJU6Mlo7Q0OCSLWslBOxVL7BOGV8hWxOfOBsi4XVWyVsqkstCnSp7BZN7V7DswWCM6sl7mPjdRmMBDe5FWsTGZslioVwdtFm5c2pCOnUzFmZb8snpakoTJoKII3S-nvfRqOv8gxVN9_RHYWui0X5lYiihJCEQ0oglfLYuxptHyia4ftWCYKvbsMEZSM4FlvCssPpTkiYSHSCNSakSwFKIv3ekk9Pe-yeaNDh6NmvP3v33oB9xPaeNERaXZgs724dLsIh1rzsrP0GyR4DfQ
  priority: 102
  providerName: Scholars Portal
Title Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection
URI https://www.ncbi.nlm.nih.gov/pubmed/36519113
https://www.proquest.com/docview/3171176570
https://www.proquest.com/docview/2754858194
https://pubmed.ncbi.nlm.nih.gov/PMC9745780
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwED-xTkK8IMbXAltlJHhC1uLEiZMnVMqqgbSC2m30LXIch1WakkEyIfgb-KO5S9yuRQJeHCl2PuQ7n-_j5zuAl4EqbWCE5Sr2Sy4jK7m2acFLYfEuLqiiR1tM45Nz-WERLZzDrXGwypVM7AR1URvykR_hPieEIqDGm-uvnKpGUXTVldDYgV0UwUk0gN23x9NPs1svC6oPvkod4h2t9yMkWYGNNjFVx97Yi7bOt22omX-iJTe2n8kDuO_0RjbqCb0Hd2z1EO6eusj4I_g1J5_2Fza1N53v4iduSWxUtcu8Ln6wWY-EtQ1razYfzeZ8XF_wgF2gpUxAGDZBdqi_0zOazfFyZbHP0KvZu7qxbFkxFDHks2nY52V7ySj1E8FnN9_23gG7qsdwPjk-G59wV2mBGyllyyXFQ-lMbioKtGC0LnMUBcLXMlVW-VKXAapVqiwIxRknythYFL5RyoQy1XkaPoFBVVd2H5hJUSkzpYxLP5c6TxJR5nHhqzzKTRQq5cHr1ZxnxqUhp2oYV1kfDg8zolDmKOTBq_Xo6z79xl_GMSTff4YcrGibuXXaZLdc5cGLdTeuMAqb6MriPGaBQqsuQs1JevC0Z4X1h8IYNWAhQg_UFpOsB1D27u2eannZZfFGQw6lpf_s37_1HO4FdOCiA9AcwKD9dmMPUQ1q8yHsqIXCNhmLoeP7YedSwPZUJtiefVz8Bi9kEIo
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fT9swED8hkLa9IPY_wDZPGk-TRZw4cfMwTR1QtQOqqQXGW-Y4DlRCCSxBiH2GfZZ9xt01SWknbXvipZXqaxLlzuef736-A3jnqcx6RliuQjfjMrCSaxulPBMWf8UJldZsi2HYP5afT4PTJfjVnoUhWmXrE6eOOi0Mxci3cZ0TQhFR4-PlFaeuUZRdbVto1Gaxb29vcMtWfhjson63PK-3d7TT501XAW6klBWXlPuj86eRSBGta50laPbC1TJSVrlSZx5CCJWlxFgMO8rYUKSuUcr4MtIJFV9Cl7-CMhHOopVPe8Mvo7uoDsIVV0UNwx5vtI0mkuKHNiF1455b-xbO083B2j_ZmXPLXW8NVhucyrq1YT2GJZs_gQeHTSb-KfwcUwz9jA3t9TRW8gOXQNbNq0lSpLdsVDNvbcmqgo27ozHfKU64x05wZ07EG9ZD8ytu6D-ajfHrwuKYoUuz3aK0bJIzdGkUIyrZ10l1zqjUFNF15682aIhk-TM4vhcdPIflvMjtS2AmQhBoMhlmbiJ10umILAlTVyVBYgJfKQfet-88Nk3Zc-q-cRHX6Xc_Jg3FjYYc2JpJX9blPv4ix1B9_xHZbHUbN36hjO-s2IG3s2Gc0ZSm0bnF9xh7CneRASI16cCL2hRmN_JDRNxC-A6oBSOZCVC18MWRfHI-rRqOG0f0zu76vx_rDTzsHx0exAeD4f4GPPLosMeUvLMJy9X3a_sKIViVvG7snsG3-55qvwFCz0Zi
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Strong+Neutralizing+Antibody+Responses+to+SARS-CoV-2+Variants+Following+a+Single+Vaccine+Dose+in+Subjects+With+Previous+SARS-CoV-2+Infection&rft.jtitle=Open+forum+infectious+diseases&rft.au=Ekstr%C3%B6m%2C+Nina&rft.au=Haveri%2C+Anu&rft.au=Solastie%2C+Anna&rft.au=Virta%2C+Camilla&rft.date=2022-12-01&rft.pub=Oxford+University+Press&rft.eissn=2328-8957&rft.volume=9&rft.issue=12&rft_id=info:doi/10.1093%2Fofid%2Fofac625
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2328-8957&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2328-8957&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2328-8957&client=summon